S.A. Montgomery

2.9k total citations
67 papers, 2.1k citations indexed

About

S.A. Montgomery is a scholar working on Pharmacology, Psychiatry and Mental health and Experimental and Cognitive Psychology. According to data from OpenAlex, S.A. Montgomery has authored 67 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Pharmacology, 24 papers in Psychiatry and Mental health and 23 papers in Experimental and Cognitive Psychology. Recurrent topics in S.A. Montgomery's work include Treatment of Major Depression (29 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (16 papers) and Schizophrenia research and treatment (12 papers). S.A. Montgomery is often cited by papers focused on Treatment of Major Depression (29 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (16 papers) and Schizophrenia research and treatment (12 papers). S.A. Montgomery collaborates with scholars based in United Kingdom, France and Austria. S.A. Montgomery's co-authors include Siegfried Kasper, G. Dunbar, D. Montgomery, David Nutt, J.A. Henry, A. W. Clare, Timothy G. Dinan, Gregory J. McDonald, I. Hindmarch and R. Amrein and has published in prestigious journals such as Biological Psychiatry, The British Journal of Psychiatry and Journal of Affective Disorders.

In The Last Decade

S.A. Montgomery

64 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S.A. Montgomery United Kingdom 22 1.0k 957 659 582 250 67 2.1k
Michael Philipp Germany 22 845 0.8× 654 0.7× 664 1.0× 495 0.9× 335 1.3× 82 2.2k
F M Quitkin United States 24 814 0.8× 935 1.0× 565 0.9× 313 0.5× 452 1.8× 43 2.0k
Ulla Lepola Finland 25 647 0.6× 880 0.9× 1.1k 1.7× 592 1.0× 371 1.5× 68 2.2k
Cathryn M. Clary United States 28 917 0.9× 1.1k 1.2× 1.2k 1.8× 1.2k 2.0× 397 1.6× 65 3.1k
Ichiro M Omori Japan 16 821 0.8× 876 0.9× 521 0.8× 517 0.9× 313 1.3× 27 2.3k
G Chouinard Canada 30 1.6k 1.6× 702 0.7× 601 0.9× 631 1.1× 330 1.3× 99 2.9k
J. Craig Nelson United States 33 1.4k 1.4× 1.3k 1.3× 613 0.9× 496 0.9× 431 1.7× 87 3.2k
J. Craig Nelson United States 21 1.1k 1.1× 1.3k 1.3× 425 0.6× 239 0.4× 253 1.0× 47 2.3k
Arif Khan United States 20 1.3k 1.2× 827 0.9× 355 0.5× 631 1.1× 440 1.8× 42 2.4k
Timothy Petersen United States 31 910 0.9× 1.2k 1.2× 716 1.1× 647 1.1× 296 1.2× 68 2.7k

Countries citing papers authored by S.A. Montgomery

Since Specialization
Citations

This map shows the geographic impact of S.A. Montgomery's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S.A. Montgomery with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S.A. Montgomery more than expected).

Fields of papers citing papers by S.A. Montgomery

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S.A. Montgomery. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S.A. Montgomery. The network helps show where S.A. Montgomery may publish in the future.

Co-authorship network of co-authors of S.A. Montgomery

This figure shows the co-authorship network connecting the top 25 collaborators of S.A. Montgomery. A scholar is included among the top collaborators of S.A. Montgomery based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S.A. Montgomery. S.A. Montgomery is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dold, Markus, Lucie Bartova, Daniel Souery, et al.. (2018). Clinical correlates of augmentation/combination treatment strategies in major depressive disorder. Acta Psychiatrica Scandinavica. 137(5). 401–412. 31 indexed citations
2.
François, C., S.A. Montgomery, Nicolas Despiégel, et al.. (2008). Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention in patients with generalised social anxiety disorder. International Journal of Clinical Practice. 62(11). 1693–1702. 10 indexed citations
3.
Baldwin, David S., S.A. Montgomery, R. Nil, & M. Lader. (2005). Discontinuation symptoms in affective disorders. ePrints Soton (University of Southampton). 1 indexed citations
4.
Stein, Dan J., et al.. (2002). Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. International Clinical Psychopharmacology. 17(4). 161–170. 40 indexed citations
5.
Montgomery, S.A.. (2001). A meta-analysis of the efficacy and tolerability of paroxetine versus tricyclic antidepressants in the treatment of major depression. International Clinical Psychopharmacology. 16(3). 169–178. 28 indexed citations
6.
Brunello, N., Siegfried Kasper, Malcolm Lader, et al.. (2000). Social phobia: diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment. Journal of Affective Disorders. 60(1). 61–74. 112 indexed citations
7.
Markowitz, John S., et al.. (2000). An assessment of selective serotonin reuptake inhibitor discontinuation symptoms with citalopram. International Clinical Psychopharmacology. 15(6). 329–333. 17 indexed citations
8.
9.
Nutt, David & S.A. Montgomery. (1996). Moclobemide in the treatment of social phobia. International Clinical Psychopharmacology. 11(Supplement 3). 77–82. 18 indexed citations
10.
Montgomery, S.A. & Siegfried Kasper. (1995). Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants. International Clinical Psychopharmacology. 9. 33–40. 127 indexed citations
11.
Montgomery, S.A.. (1995). Safety of mirtazapine: a review. International Clinical Psychopharmacology. 10(Supplement 4). 37–45. 135 indexed citations
12.
Montgomery, S.A., J.A. Henry, Gregory J. McDonald, et al.. (1994). Selective serotonin reuptake inhibitors. International Clinical Psychopharmacology. 9(1). 47–54. 211 indexed citations
13.
Montgomery, S.A.. (1993). Psychopharmacology of panic. Oxford University Press eBooks. 18 indexed citations
14.
Montgomery, S.A.. (1993). A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. European Neuropsychopharmacology. 3(2). 143–152. 133 indexed citations
15.
Montgomery, S.A. & G. Dunbar. (1993). Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. International Clinical Psychopharmacology. 8(3). 189–196. 148 indexed citations
16.
Montgomery, S.A.. (1993). Obsessive compulsive disorder is not an anxiety disorder. International Clinical Psychopharmacology. 8. 57–62. 13 indexed citations
17.
Montgomery, S.A.. (1993). Suicide prevention and serotonergic drugs. International Clinical Psychopharmacology. 8. 83–86. 6 indexed citations
18.
Montgomery, S.A., et al.. (1992). SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OCD. Clinical Neuropharmacology. 15. 255A–256A. 2 indexed citations
19.
Montgomery, S.A., et al.. (1978). Estimation of maximal oxygen consumption from a stand-up bicycle test.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 18(3). 271–6. 3 indexed citations
20.
Braithwaite, R A, et al.. (1978). A radioimmunoassay for amitriptyline and nortriptyline [proceedings].. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 63(2). 370P–371P. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael Philipp Breakdown of academic impact, for papers by F M Quitkin Breakdown of academic impact, for papers by Ulla Lepola Breakdown of academic impact, for papers by Cathryn M. Clary Breakdown of academic impact, for papers by Ichiro M Omori Breakdown of academic impact, for papers by G Chouinard Breakdown of academic impact, for papers by J. Craig Nelson Breakdown of academic impact, for papers by J. Craig Nelson Breakdown of academic impact, for papers by Arif Khan Breakdown of academic impact, for papers by Timothy Petersen
Rankless by CCL
2026